Monday, September 30, 2019
Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced today the acquisition of Nalpropion Pharmaceuticals. As a result of this acquisition, Currax now owns the world-wide rights to CONTRAVE, which is the number one prescribed weight-loss brand medication in the United States.
CONTRAVE is a prescription weight-loss medicine with patent protection until 2034. CONTRAVE works in two parts of the brain to help some adults control their eating, resulting in sustained weight loss. Contrave is indicated to help patients with a body mass index (BMI) of 30kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least on weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, to lose weight and maintain their weight loss.
“It is exciting to announce our second acquisition in as many days” said George Hampton, chief executive officer of Currax Pharmaceuticals LLC. “This acquisition bolsters our Branded portfolio and demonstrates that we are successfully executing on our business strategy to acquire clinically differentiated medicines with high potential for growth and extended IP life.”
CONTRAVE was approved by FDA on September 10, 2014.
